Sanofi stock holds firm as vaccine updates lift the story
Published on 09/01/2026 at 09:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock (FR0000127771) traded at $44.82 on August 29, 2026, with a market capitalization of $107.39 billion and a day-on-day change of minus 0.03 percent. That market snapshot gives the French drugmaker a sizeable valuation base as investors weigh a recent vaccine update and the latest quarterly numbers.
Vaccine angle
Recent reporting on August 31, 2026 linked Sanofi to the new COVID vaccine rollout for the 2026-27 season, with updated shots aimed at the XFG variant. The same reporting also pointed to the broader respiratory-season backdrop, which keeps vaccine execution relevant for the shares.
On the home listing in Paris, Sanofi closed at EUR 77.25 on August 28, 2026, after a daily move of minus 0.04 percent and a five-day change of minus 2.14 percent. The stock also stood 6.61 percent lower for the year at that point, so the recent catalyst has landed against a weaker tape rather than a stretched rally.
Quarterly numbers
The latest reported quarter ended June 30, 2026, with earnings per share of $0.35 versus $0.39 a year earlier and revenue of $11.95 billion versus $10.65 billion in the prior-year quarter. That means sales rose 12.2 percent year over year even as EPS eased by 10.3 percent, a split that puts margin and mix more in focus than top-line growth alone.
A second figure stands out: the same quarter's revenue increase of $1.30 billion helped Sanofi keep growth visible while the share price remained close to a recent European close of EUR 77.25. For investors, the comparison is straightforward - the operating line improved faster than the per-share result.
What matters next
Sanofi's vaccine portfolio remains the clearest product-level thread in the current story, and the updated COVID shot rollout keeps that line of business relevant heading into the fall season. In the market, the gap between a $44.82 US quote and a $107.39 billion market value leaves the stock anchored to scale rather than momentum.
Dupixent and vaccines
Dupixent remains Sanofi's best-known growth product, but the current discussion is broader than one franchise. The more immediate investor question is whether vaccine execution and the June 30, 2026 quarter can support a steadier rerating after the shares' year-to-date slide.
Closing view
As of August 29, 2026, Sanofi's US-quoted shares were at $44.82. On August 28, 2026, the Paris listing closed at EUR 77.25, giving investors two live reference points for the same business.
Fact box
Company: Sanofi S.A.
ISIN: FR0000127771
Ticker: SAN / SAN.PA
Exchange: Nasdaq / Euronext Paris
Price (as of August 29, 2026, 4:00 p.m. ET): $44.82 USD
Market cap: $107.39 billion (as of August 29, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: CAC 40
